BR112016011727A2 - Antagonistas de gastrina para o tratamento e prevenção de osteoporose - Google Patents

Antagonistas de gastrina para o tratamento e prevenção de osteoporose

Info

Publication number
BR112016011727A2
BR112016011727A2 BR112016011727A BR112016011727A BR112016011727A2 BR 112016011727 A2 BR112016011727 A2 BR 112016011727A2 BR 112016011727 A BR112016011727 A BR 112016011727A BR 112016011727 A BR112016011727 A BR 112016011727A BR 112016011727 A2 BR112016011727 A2 BR 112016011727A2
Authority
BR
Brazil
Prior art keywords
gastrin
treatment
treating
osteoporosis
prevention
Prior art date
Application number
BR112016011727A
Other languages
English (en)
Inventor
Mark Modlin Irvin
KIDD Mark
Original Assignee
CL BioSciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52118000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016011727(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by CL BioSciences LLC filed Critical CL BioSciences LLC
Publication of BR112016011727A2 publication Critical patent/BR112016011727A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

ANTAGONISTAS DE GASTRINA PARA O TRATAMENTO E PREVENÇÃO DE OSTEOPOROSE. As modalidades fornecidas têm por base, em alguns aspectos, a demonstração no presente documento de uma função para gastrina na regulação do eixo intestino-ovário de envelhecimento e efeitos de alvejamento da atividade de gastrina na reversão de perda óssea mediada por gastrina. São fornecidos métodos, composições e agentes, que incluem antagonistas de gastrina, para o tratamento, melhora ou prevenção de afecções e doenças ósseas. Os métodos para o tratamento de uma afecção ou doença óssea associada à hipergastrinemia em um indivíduo que necessita desse tratamento, pode compreender a administração ao indivíduo de ao menos uma dose de uma quantidade terapeuticamente eficaz de um agente de alvejamento de receptor de gastrina, tratando, assim, a afecção ou doença óssea associada à hipergastrinemia.
BR112016011727A 2013-11-22 2014-11-21 Antagonistas de gastrina para o tratamento e prevenção de osteoporose BR112016011727A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361907980P 2013-11-22 2013-11-22
PCT/US2014/066832 WO2015077572A1 (en) 2013-11-22 2014-11-21 Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis

Publications (1)

Publication Number Publication Date
BR112016011727A2 true BR112016011727A2 (pt) 2017-08-08

Family

ID=52118000

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011727A BR112016011727A2 (pt) 2013-11-22 2014-11-21 Antagonistas de gastrina para o tratamento e prevenção de osteoporose

Country Status (14)

Country Link
US (1) US10709714B2 (pt)
EP (1) EP3071206B1 (pt)
JP (1) JP6502939B2 (pt)
KR (1) KR102254957B1 (pt)
CN (1) CN106163527A (pt)
AU (1) AU2014352875B2 (pt)
BR (1) BR112016011727A2 (pt)
CA (1) CA2929858C (pt)
DK (1) DK3071206T3 (pt)
ES (1) ES2870538T3 (pt)
MX (1) MX2016006657A (pt)
PL (1) PL3071206T3 (pt)
RU (1) RU2693484C1 (pt)
WO (1) WO2015077572A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10881667B2 (en) 2018-10-30 2021-01-05 City University Of Hong Kong Method and composition for treating epilepsy
US11285161B2 (en) 2019-04-26 2022-03-29 City University Of Hong Kong Method and composition for treating mental disorder and pain associated with nerve damage
CN110935005A (zh) * 2019-11-19 2020-03-31 宁波大学 一种丙谷二肽的新用途
CN115770266B (zh) * 2023-01-30 2023-05-09 云南中医药大学 一种用于治疗绝经后骨质疏松的药物组合物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0348523A4 (en) * 1987-12-22 1991-10-09 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their medicinal use
EP0411668B2 (en) 1989-08-04 1998-11-11 MERCK SHARP & DOHME LTD. Central cholecystokinin antagonists for treatment of psychiatric disorders
US5399565A (en) 1990-07-17 1995-03-21 Eli Lilly And Company Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
AU656754B2 (en) 1990-12-25 1995-02-16 Yamanouchi Pharmaceutical Co., Ltd. Novel benzodiazepine derivative
CA2110986A1 (en) 1991-07-12 1993-01-21 Geoffrey Neil Woodruff Cholecystokinin antagonists useful in the treatment of panic attacks
JP3239364B2 (ja) * 1991-10-11 2001-12-17 ウェルファイド株式会社 骨粗鬆症治療薬およびジアゼピン化合物
AU3247593A (en) 1991-12-20 1993-07-28 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
IL104853A (en) 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
MY128102A (en) 1993-02-17 2007-01-31 Chugai Pharmaceutical Co Ltd Indolin-2-one-derivatives
GB2282595A (en) 1993-08-25 1995-04-12 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives
IT1261255B (it) 1993-09-09 1996-05-09 Rotta Research Lab Derivati acidi poliamidici ad attivita' antigastrinica, procedimento per la loro preparazione e loro uso farmaceutico.
US5750353A (en) 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
IL124808A0 (en) 1995-12-11 1999-01-26 New England Medical Center Inc Assay for and uses of peptide hormone receptor ligands
US5922883A (en) 1996-04-03 1999-07-13 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20040001842A1 (en) 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
EP0981369B1 (en) 1997-05-12 2004-11-17 Aphton Corporation Immunogenic compositions to the cck-b/gastrin-receptor and methods for the treatment of tumors
WO1999059628A2 (en) 1998-05-15 1999-11-25 Aphton Corporation Combination therapy for the treatment of tumors
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6500854B1 (en) 1999-01-29 2002-12-31 Chugai Sei Yaku Kabushiki Kaisha Chondrongenesis promotors and indolin-2-one derivatives
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US20030191279A1 (en) 1999-08-27 2003-10-09 Goldstein Steven Wayne Urea derivatives useful as anticancer agents
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
EP1661564A1 (fr) 1999-11-05 2006-05-31 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Nouveaux composés hétérocycliques et leur application à titre de médicaments
JP2003513995A (ja) 1999-11-19 2003-04-15 アクスクシーマ ファルマシューティカルス アクチェンゲゼルシャフト ヘリコバクターピロリにより誘発される胃腸疾患の阻害剤
CA2404852A1 (en) 2000-04-10 2001-10-18 Timothy C. Wang Diagnosis and treatment of gastrointestinal disease
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
WO2002076499A2 (en) 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
JPWO2002087620A1 (ja) 2001-04-27 2004-08-12 中外製薬株式会社 軟骨形成促進剤
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
EP1391203A4 (en) 2001-05-11 2005-09-14 Astellas Pharma Inc ANTITUMORAL AGENTS
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US20060003993A1 (en) 2001-11-13 2006-01-05 James Black Foundation Limited Benzotriazepnes as gastrin and cholecystokinin receptor ligands
MXPA04008680A (es) 2002-02-19 2004-12-06 Pharmacia Italia Spa Derivados de pirazol triciclicos, procedimientos para su preparacion y su uso como agentes anti-tumorales.
DE10207037A1 (de) 2002-02-20 2003-08-28 Bayer Cropscience Gmbh 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US20030049698A1 (en) 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
NZ542491A (en) 2003-03-28 2009-04-30 Janssen Pharmaceutica Nv Benzo[1,2,5]thiadiazole compounds as CCK2 modulators
US7524837B2 (en) 2003-05-12 2009-04-28 Janssen Pharmaceutica N.V. Benzotriazapinone salts and methods for using same
GB0310865D0 (en) 2003-05-12 2003-06-18 Black James Foundation Gastrin and cholecystokinin receptor ligands
US20050042283A1 (en) 2003-07-11 2005-02-24 University Of Massachusetts Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer
PT1651621E (pt) 2003-08-08 2008-09-30 Janssen Pharmaceutica Nv Compostos de 2-(quinoxalin-5-ilsulfonilamino)-benzamida como moduladores de cck2
US20070293482A1 (en) 2004-03-19 2007-12-20 Novartis Pharmaceuticals Corporation Process for Preparing Benzodiazepines
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7947833B2 (en) 2004-08-04 2011-05-24 Janssen Pharmaceutica Nv Preparation of quinoxaline compounds
BRPI0516027A (pt) 2004-09-24 2008-08-19 Janssen Pharmaceutica Nv compostos de sulfonamida
US20080124741A1 (en) 2004-10-12 2008-05-29 Heng Dai Canine Cholecystokinin 1 Receptor Materials And Their Use
US20090239841A1 (en) 2004-10-27 2009-09-24 Hutchison Alan J Diaryl Ureas as CB1 Antagonists
WO2006052542A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
GB0425196D0 (en) 2004-11-15 2004-12-15 Black James Foundation Gastrin and cholecystokinin receptor ligands
CA2591412A1 (en) 2004-12-17 2006-06-22 Pfizer Inc. Chromane derivatives useful as acid pump antagonists
KR101285047B1 (ko) 2005-01-19 2013-07-10 제리아 신야쿠 고교 가부시키 가이샤 항종양제
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
US8053413B2 (en) 2005-06-06 2011-11-08 The Board Of Trustees Of The University Of Illinois Methods for treating sleep disorders by cholecystokinin (CCK) receptor B antagonists
CA2608582A1 (en) 2005-06-14 2006-12-21 Pfizer Inc. Chromane substituted benzimidazole derivatives as acid pump antagonists
ATE425791T1 (de) 2005-07-29 2009-04-15 Rottapharm Spa Kombination aus itriglumid und ppi zur behandlung von gastrointestinalen- und assozierten krankheiten
WO2007026218A2 (en) 2005-09-01 2007-03-08 Pfizer Japan Inc. Chromane substituted 2-alkyl imidazopyridine derivatives and use thereof as acid pump antagonists
WO2007031860A1 (en) 2005-09-15 2007-03-22 Pfizer Japan Inc. Indane substituted benzimidazoles and their use as acid pump inhibitors
WO2007072142A2 (en) 2005-12-19 2007-06-28 Pfizer Japan Inc. Benzimidazole-5-carboxamide derivatives
BRPI0620081B8 (pt) 2005-12-19 2021-05-25 Pfizer composto e composição farmacêutica.
BRPI0708808A2 (pt) 2006-03-17 2011-06-14 Raqualia Pharma Inc Derivados de cromano
EP2004631A1 (en) 2006-04-12 2008-12-24 Merck Patent GmbH N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
FR2901472B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et des agents denaturants
FR2901473B1 (fr) 2006-05-24 2010-08-13 Oreal Procede de defrisage des fibres keratiniques avec un moyen de chauffage et une amide
ATE512969T1 (de) 2006-09-21 2011-07-15 Raqualia Pharma Inc Benzimidazolderivate als selektive säurepumpenhemmer
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2008059373A1 (en) 2006-11-17 2008-05-22 Raqualia Pharma Inc. Imidazo [1, 2-a] pyrazine derivatives and their use as acid pump antagonists
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物
WO2008114123A1 (en) 2007-03-21 2008-09-25 Raqualia Pharma Inc. Spiro benzimidazole derivatives as acid pump inhibitors
WO2008124524A2 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
WO2008124518A1 (en) 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Oxo-dihydroisoindole sulfonamide compounds as modulators of the cck2 receptor
AU2008267444A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
RU2379043C2 (ru) * 2007-08-02 2010-01-20 Закрытое акционерное общество "Биологические исследования и системы" Фармацевтическая композиция для профилактики и лечения остеопороза у женщин в период менопаузы
US20110105515A1 (en) 2007-08-07 2011-05-05 President And Fellows Of Harvard College Targeting the oncoprotein nucleophosmin
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
AU2010231439A1 (en) 2009-03-31 2011-10-27 Zeria Pharmaceutical Co., Ltd. Method for manufacturing 1,5-benzodiazepine derivative
WO2011004882A1 (ja) 2009-07-09 2011-01-13 ラクオリア創薬株式会社 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤
CA2775204A1 (en) 2009-09-24 2011-03-31 Centro Nacional De Investigaciones Oncologicas (Cnio) Fused imidazo [3, 2 - d] pyraz ines as pi3 kinase inhibitors
HUE043536T2 (hu) 2009-10-06 2019-08-28 Millennium Pharm Inc PDK1 inhibitorként alkalmazható heterociklusos vegyületek
AU2010319298B2 (en) 2009-11-13 2015-11-05 Plastipak Packaging, Inc. Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions
WO2011063164A2 (en) 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
AU2011242683A1 (en) 2010-04-23 2012-12-13 Kineta, Inc. Anti-viral compounds
US9000054B2 (en) 2010-08-12 2015-04-07 Senomyx, Inc. Method of improving stability of sweet enhancer and composition containing stabilized sweet enhancer
AU2011329623A1 (en) 2010-11-18 2013-07-11 Pier Pharmaceuticals Low dose cannabinoid medicaments
US20120231083A1 (en) 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
CA2818903C (en) 2010-12-14 2021-03-23 Electrophoretics Limited 5-(1,3-benzoxazol-2-yl)-4-(pyridin-4-yl)pyrimidin-2-amine and its use as a casein kinase 1delta inhibitor
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
US9085595B2 (en) 2011-11-07 2015-07-21 Massachusetts Institute Of Technology Tungsten oxo alkylidene complexes for Z selective olefin metathesis
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors

Also Published As

Publication number Publication date
JP6502939B2 (ja) 2019-04-17
RU2693484C1 (ru) 2019-07-03
PL3071206T3 (pl) 2022-01-17
DK3071206T3 (da) 2021-05-25
US10709714B2 (en) 2020-07-14
AU2014352875B2 (en) 2019-10-24
CA2929858C (en) 2022-03-29
ES2870538T3 (es) 2021-10-27
CA2929858A1 (en) 2015-05-28
KR102254957B1 (ko) 2021-05-25
AU2014352875A1 (en) 2016-05-26
JP2016538295A (ja) 2016-12-08
EP3071206A1 (en) 2016-09-28
MX2016006657A (es) 2016-10-12
EP3071206B1 (en) 2021-02-17
CN106163527A (zh) 2016-11-23
KR20160088891A (ko) 2016-07-26
WO2015077572A1 (en) 2015-05-28
US20150148339A1 (en) 2015-05-28
AU2014352875A8 (en) 2016-06-30
RU2016124538A (ru) 2017-12-27

Similar Documents

Publication Publication Date Title
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112018008358A2 (pt) ?composições e métodos para terapia relacionada à microbiota fecal?
BR112017021688A2 (pt) composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112017026739A2 (pt) compostos para uso no tratamento de distúrbios neuromusculares
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
BR112015006093A2 (pt) combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112015021371A2 (pt) uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112016025312A2 (pt) variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
BR112018076639A2 (pt) quimioterapias de combinação
BR112014019399A2 (pt) métodos de tratamento da fibrose

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]